
Cellworks Launches Breakthrough Platform to Predict Chemo-Immunotherapy Response in Metastatic NSCLC
Cellworks Unveils Breakthrough in Predicting Chemo-Immunotherapy Benefit for Patients with Metastatic NSCLC Cellworks Group Inc., a leader in personalized therapy decision support and best-in-class patient-specific treatment response simulations (PTRS), has…












